Search Medical Condition
Please enter condition
Please choose location
 

Kokkola, Finland Clinical Trials

A listing of Kokkola, Finland clinical trials actively recruiting patients volunteers.

RESULTS

Found (8) clinical trials

The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)

Coronary bifurcation lesions with stenosis in a large side branch may require complex stent implantation techniques with an elevated risk of suboptimal treatment results. Intra vascular optical coherence tomography (OCT) enables improved procedural control of correctable factors and may lead to optimized implantation results. It is unknown if routine, systematic ...

Phase N/A

0.0 miles

Learn More »

Efficacy Safety and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults

This randomized, observer-blind, placebo-controlled multicenter, Phase 3 study will be conducted at multiple sites. The composition of the Quadrivalent VLP Influenza Vaccine to be used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins expressed as VLPs for the 2017-2018 influenza virus strains. Approximately ...

Phase

0.0 miles

Learn More »

Immunogenicity and Safety of Sci-B-Vac to Engerix-B in Adults 18 Years Old and Superiority in Adults 45 Years Old.

This study is a double-blind randomized controlled trial designed to establish the non-inferiority of Sci-B-Vac compared to Engerix-B in adults 18 years old and the superiority of Sci-B-Vac compared to Engerix-B in adults 45 years old. Study subjects will be randomized 1:1 to receive either a total of 3 injections ...

Phase

0.0 miles

Learn More »

Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax ) to the Drug (Everolimus) -Eluting Stent (Synergy ) in Acute Coronary Syndrome

Coronary artery disease (CAD) is the most frequent cause of death, accounting for approximately 13% of all deaths. In western countries, the incidence of ST-segment elevation myocardial infarction (STEMI) is around 77/100 000/year, whereas in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), the incidence is 132/100 000/year. Thus, the ...

Phase

0.0 miles

Learn More »

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix During Pregnancy or Immediately Post-delivery

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' Infanrix hexa, given in the primary vaccination schedule to infants born to pregnant women who participated in study 116945 [DTPA (BOOSTRIX)-047]. This study will help us evaluate if the presence of transplacentally transferred maternal antibodies ...

Phase

2.35 miles

Learn More »

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix During Pregnancy or Immediately Post-delivery

The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa booster dose given at 11-18 months of age to infants who received primary vaccination at 6-14 weeks. All infants in this booster study were born to pregnant women who participated in the study 116945 ...

Phase

2.35 miles

Learn More »

Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Infants Starting at Age 6-12 Weeks

Experimental design: Phase IIIA, observer-blind, randomised (1:1:1:1), controlled, multi-centric, with four parallel groups and a staggered enrolment (Part A and Part B). Duration of the study: The intended duration of the study, per subject, will be approximately 7-8 months including the 6 months of extended safety follow-up period after the ...

Phase

2.35 miles

Learn More »

Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of QIVc in Subjects 2 to 18 Years of Age

The randomized, observer-blind non-influenza comparator controlled study is intended to demonstrate the efficacy, immunogenicity, safety and tolerability of Seqirus' cell-based inactivated quadrivalent vaccine (QIVc) in subjects ≥2 years to <18 years of age

Phase

2.35 miles

Learn More »